

VACCINATING DOGS AGAINST LYME DISEASE: TWO POINTS OF VIEW

Meryl P. Littman, VMD, Diplomate ACVIM
University of Pennsylvania

Richard E. Goldstein, DVM, Diplomate ACVIM & ECVIM (Companion Animal)
The Animal Medical Center, New York City

Littman References

1. Fiala J. Researcher creates tool to gauge vaccine needs. *DVM360 Magazine* 2003; available at <http://veterinarynews.dvm360.com/dvm/article/articleDetail.jsp?id=70130>.
2. CDC website; available at <http://www.cdc.gov/lyme/>.
3. Littman MP, Goldstein RE, Labato MA, et al. ACVIM small animal consensus statement on lyme disease in dogs: diagnosis, treatment, and prevention. *J Vet Intern Med* 2006; 20(2):422-434.
4. Speck S, Reiner B, Streich WJ, et al. Canine borreliosis: A laboratory diagnostic trial. *Vet Microbiol* 2007; 120:132-141.
5. Littman MP. State-of-the-art-review: Lyme nephritis. *J Vet Emerg Crit Care* 2013; 23:163-173.
6. Littman MP. Protein-losing nephropathy in small animals. In Acierno MJ, Labato MA (eds): *Kidney disease and renal replacement therapies. Vet Clin N Am Small Animal Pract* 2011; 41(1):31-62.
7. Goldstein RE, Corder AP, Sandler JL, et al. Microalbuminuria and comparison of serologic testing for exposure to *Borrelia burgdorferi* in nonclinical Labrador and golden retrievers. *J Vet Diagn Invest* 2007; 19:294-297.
8. Littman MP, Wiley CA, Raducha MG, Henthorn PS. Glomerulopathy and mutations in NPHS1 and KIRREL2 in soft coated wheaten terrier dogs. *Mamm Genome* 2013; 24:119-126.
9. Beall MJ, Chandrashekar R, Eberts MD, et al. Serological and molecular prevalence of *Borrelia burgdorferi*, *Anaplasma phagocytophilum*, and *Ehrlichia* species in dogs from Minnesota. *Vector Borne Zoonotic Dis* 2008; 8:455-464.
10. Topfer KH, Straubinger RK. Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent: a study with five commercial vaccines using two different vaccination schedules. *Vaccine* 2007; 25:314-326.
11. Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. *JAVMA* 2005; 227(7):1102-1108.
12. Klingborg DJ, Husted DR, Curry-Galvin EA, et al. AVMA council on biologic and therapeutic agents' report on cat and dog vaccines. *JAVMA* 2002; 221:1401-1407.
13. Gondolf KB, Mihatsch M, Curschellas E, et al. Induction of experimental allergic arthritis with outer surface proteins of *Borrelia burgdorferi*. *Arthritis Rheum* 1994; 37:1070-1077.
14. Steere AC, Drouin EE, Glickstein LJ. Relationship between immunity to *Borrelia burgdorferi* outer-surface protein A (OspA) and Lyme arthritis. *Clin Inf Dis* 2011;52 (Suppl 3):S259-S265.
15. Lim LC, England DM, DuChateau BK, et al. Development of destructive arthritis in vaccinated hamsters challenged with *Borrelia burgdorferi*. *Infect Immun* 1994; 62:2825-2833.
16. Croke CL, Munson EL, Lovrich SD, et al. Occurrence of severe destructive Lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with *Borrelia burgdorferi*. *Infect Immun* 2000; 68:658-663.
17. Littman MP. Perspectives in veterinary medicine: Why I don't use Lyme disease vaccines. *Comp Cont Ed Pract Vet* 1997; 19(11):1269, 1272, 1274-1275.
18. Littman MP. Immune-mediated reactions against Lyme vaccines. *ACVIM Proc* 2000; pp 629-630.
19. Dambach DM, Smith CA, Lewis RM, Van Winkle TJ. Morphologic, immunohistochemical, and ultrastructural characterization of a distinctive renal lesion in dogs putatively associated with *Borrelia burgdorferi* infection: 49 cases (1987-1992). *Vet Pathol* 1997; 34:85-96.

20. Littman MP. A matter of opinion: Should we treat asymptomatic, nonproteinuric Lyme-seropositive dogs with antibiotics? *Clin Brief* 2011; 9:13-16.
21. Dai J, Wang P, Adusumilli S, et al. Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. *Cell Host Microbe* 2009; 6(5):482-492.
22. Schuijt TJ, Hovius JW, van der Poll T, et al. Lyme borreliosis vaccination: The facts, the challenge, the future. *Trends Parasitol* 2011; 27:40-47.
23. Embers ME, Narasimhan S. Vaccination against Lyme disease: Past, present, and future. *Front Cell Inf Microbio* 2013; 3(6):1-15.

Goldstein References

1. Kuehn BM. CDC estimates 300,000 US cases of Lyme disease annually. *JAMA* 2013; 310(11):1110.
2. Grimm D, Tilly K, Byram R, et al. Outer-surface protein C of the Lyme disease spirochete: A protein induced in ticks for infection of mammals. *Proc Natl Acad Sci USA* 2004; 101(9):3142-3147.
3. Nadelman RB, Hanincová K, Priyanka Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. *N Engl J Med* 2012; 367:1883-1888.
4. Embers ME, Narasimhan S. Vaccination against Lyme disease: Past, present, and future. *Front Cell Infect Microbiol* 2013; 3:6.
5. Barrett PN, Portsmouth D. A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies. *Expert Rev Vaccines* 2013; 12(9):973-975.
6. Plotkin SA. Correcting a public health fiasco: The need for a new vaccine against Lyme disease. *Clin Infect Dis* 2011; 52(3):S271-S275.
7. LaFleur RL, Callister SM, Dant JC, et al. One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. *Clin Vaccine Immunol* 2010; 17(5):870-874.
8. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. *Clin Vaccine Immunol* 2009; 16(2):253-259.
9. Conlon JA, Mather TN, Tanner P, et al. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with *Borrelia burgdorferi*. *Vet Ther* 2000; 1(2):96-107.
10. Levy SA, Lissman BA, Ficke CM. Performance of a *Borrelia burgdorferi* bacterin in borreliosis-endemic areas. *JAVMA* 1993; 202(11):1834-1838.
11. Hebert D, Eschner A. Seroprevalence of *Borrelia burgdorferi*-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic. *Vet Ther* 2010; 11(3).
12. Personal communication with Jody Sandler, DVM, Director of Veterinary Services, Guiding Eyes for the Blind, Yorktown, New York.
13. Littman MP, Goldstein RE, Labato MA, et al. ACVIM small animal consensus statement on Lyme disease in dogs: Diagnosis, treatment, and prevention. *J Vet Intern Med* 2006; 20(2):422-434.
14. Goldstein RE, Atwater DZ. Serologic and circulating immune complex analysis in dogs naturally infected with *Borrelia burgdorferi* (abstract). *ACVIM Forum Proc* 2006.
15. Goldstein RE, Atwater DZ. Serology and circulating immune complexes in dogs naturally infected with *Borrelia burgdorferi* before and after doxycycline therapy (abstract). *ACVIM Forum Proc* 2006.